Ropanicant

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Ropanicant (SUVN-911) is an investigational new drug under development by Suven Life Sciences Ltd for the treatment of major depressive disorder (MDD) and certain neurological conditions. It acts as an antagonist of the α4β2 nicotinic acetylcholine receptor (nAChR), a target involved in mood regulation and cognitive function. Ropanicant has been shown to increase levels of serotonin and brain-derived neurotrophic factor (BDNF) in the cortex, which may contribute to its antidepressant effects. By modulating neurotransmitter levels—particularly serotonin—it is intended to produce rapid antidepressant effects while minimizing the side effects commonly associated with traditional antidepressants.

Ropanicant (SUVN-911) is an investigational new drug under development by Suven Life Sciences Ltd for the treatment of major depressive disorder (MDD) and certain neurological conditions. It acts as an antagonist of the α4β2 nicotinic acetylcholine receptor (nAChR), a target involved in mood regulation and cognitive function. Ropanicant has been shown to increase levels of serotonin and brain-derived neurotrophic factor (BDNF) in the cortex, which may contribute to its antidepressant effects. By modulating neurotransmitter levels—particularly serotonin—it is intended to produce rapid antidepressant effects while minimizing the side effects commonly associated with traditional antidepressants.

See also

Tebanicline Neonicotinoids

Text derived from https://en.wikipedia.org/w/index.php?oldid=1370748825 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.